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Summary  
Glioblastoma (GBM) is an aggressive brain tumor driven by cells with hallmarks 
of neural stem (NS) cells. GBM stem cells frequently express high levels of the 
transcription factors FOXG1 and SOX2. Here we show that increased expression of 
these factors restricts astrocyte differentiation and can trigger de-differentiation to a 
proliferative NS cell state. Transcriptional targets include cell cycle and epigenetic 
regulators (e.g. Foxo3, Plk1, Mycn; and Dnmt1, Dnmt3b, Tet3). Foxo3 is a critical 
repressed downstream effector that is controlled via a conserved FOXG1/SOX2-
bound cis-regulatory element. Foxo3 loss, combined with exposure to the DNA 
methylation inhibitor 5-Azacytidine, enforces astrocyte de-differentiation. DNA 
methylation profiling in differentiating astrocytes identifies changes at multiple 
polycomb targets, including the promoter of Foxo3. In patient-derived GBM stem cells 
CRISPR/Cas9 deletion of FOXG1 does not impact proliferation in vitro; however, upon 
transplantation in vivo FOXG1 null cells display increased astrocyte differentiation and 
upregulate FOXO3. By contrast, SOX2 ablation attenuates proliferation and mutant 
cells cannot be expanded in vitro. Thus, FOXG1 and SOX2 operate in complementary 
but distinct roles to fuel unconstrained self-renewal in GBM stem cells via 
transcriptional control of core cell cycle and epigenetic regulators. 
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Introduction 
 Glioblastoma multiforme (GBM) is a highly aggressive brain tumor driven by 
neural stem cell-like cells. It is increasingly clear that the transcriptional and epigenetic 
mechanisms that control the initiation and maintenance of neural stem and progenitor 
cells are hijacked and deregulated in GBMs (Patel et al., 2014; Singh et al., 2003; 
Suvà et al., 2014). Neurodevelopmental transcription factors (e.g. bHLH, SOX, FOX 
and HOX families) are known to be critical regulators of neural stem cell self-renewal 
and differentiation. Transcription factors are, however, difficult to ‘drug’ with small 
molecules. Improved understanding of the role of these master regulators and their 
key downstream effectors is needed. 
We previously reported that FOXG1 is one of the most consistently 
overexpressed genes when comparing primary cultures of GBM-derived neural stem 
(GNS) cells and genetically normal NS cells (Engström et al., 2012). FoxG1 is a 
member of the forkhead box family of transcription factors. During development, it has 
an essential role in regulating forebrain radial glia/ neural progenitor cell proliferation 
and limiting premature differentiation (Martynoga et al., 2005; Mencarelli et al., 2010; 
Xuan et al., 1995). 
Although FOXG1 is not genetically amplified in glioma, FOXG1 mRNA levels in 
primary tumors are inversely correlated with patient survival (Verginelli et al., 2013). 
Recently, Liu et al. demonstrated that the oncogenic EGFR truncation (EGFRvIII) –
found in a significant proportion of 'classical' subtype GBMs – operates in part by 
triggering expression of FOXG1 (Liu et al., 2015). FOXG1 protein has previously been 
shown to operate by attenuating the cytostatic effects of TGF-beta signalling by 
binding and sequestration of FOXO/SMAD complexes in established glioblastoma cell 
lines (Seoane et al., 2004). These findings suggest that increased levels of FOXG1 in 
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GBM might be functionally important in driving tumor growth. Evidence in favor of this 
hypothesis has been provided by shRNA knockdown of FOXG1 in GBM stem cells, 
which leads to reduced proliferation of the resulting tumors (Verginelli et al., 2013). 
Despite these observations, we have poor understanding of the functional 
consequences of its increased levels and the downstream transcriptional targets in 
both NS cells and GBM stem cells.  
SOX2 is an established stem cell ‘master’ regulator highly expressed in multiple 
tissue stem cells, including various types of neural stem and progenitor cells (Arnold et 
al., 2011). It has important functions within the pluripotent epiblast, embryonic stem 
cell cultures, neuroepithelial progenitors and in multipotent radial glia (fetal, postnatal 
and adult) (Avilion et al., 2003). In Xenopus, chick, and mouse, the constitutive 
expression of Sox2 re-specifies gastrulation stage progenitor cells into 
neuroectoderm, at the expense of other lineages (Kishi et al., 2000; Zhao et al., 2004). 
It is genetically amplified in ~4% of GBM samples (Brennan et al., 2013). Knockdown 
experiments have indicated that SOX2 is required to sustain the aggressive growth 
and infiltrative behavior of GBMs (Gangemi et al., 2009;  Alonso et al., 2011).  
Together these studies point to an important role for FOXG1 and SOX2 in NS 
cells and their potential deregulation in GBM. FoxG1 and Sox2 are also established 
reprogramming factors: forced co-expression can trigger direct reprogramming of 
fibroblasts to an NS cell-like state (Lujan et al., 2012). The excessive levels or activity 
of these factors in GBM may therefore operate intrinsically to restrict tumour cell 
differentiation through perpetual reprogramming to a radial-glia like NS cell state. 
Despite the frequent expression of FOXG1/SOX2 in GBM, we have only a poor 
understanding of their downstream transcriptional targets and how they operate to 
drive proliferation and limit terminal differentiation. 
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Here we define genome-wide transcriptional targets of both factors, and find 
that FOXG1/SOX2 can act at shared target loci encoding core cell cycle and 
epigenetic regulators. Loss of function studies suggest they have context-specific 
functions, with SOX2 essential for proliferation, while FOXG1 protects cells from 
differentiation cues, both in vitro and in vivo. These two transcriptional regulators 
therefore cooperate in functionally distinct but complementary roles to limit astrocyte 
differentiation commitment in GBM and enforce the proliferative NS cell-like 
phenotype. 
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Results 
Human GBM stem cells express elevated levels of FOXG1 and exhibit an open 
chromatin profile enriched for FOX/SOX motifs 
To explore the role of FOXG1 we first extended our previous finding of elevated 
FOXG1 mRNA expression in GBM by assessing levels of FOXG1 protein. FOXG1 
protein is consistently and highly expressed across a set of nine independent patient-
derived GNS cell lines when compared to NS cells (Fig. 1A). It is also increased in a 
mouse glioma-initiating cell line (Supplemental Fig. S1). SOX2 protein levels are high 
in both NS and GNS cells. OLIG2, a developmental TF often expressed in GBM, is 
more variably expressed between GNS lines (Fig. 1A). 
 High levels of FOXG1 in GNS cells might contribute to a modified chromatin 
landscape compared to karyotypically normal NS cells. To assess chromatin 
accessibility genome-wide in GNS and NS cells we performed ATAC-seq (Buenrostro 
et al., 2013). Seven independent human GNS lines (G7, G14, G19, G25, G26, G32, 
G144, G166, G179), and four human NS cell controls, were assayed in biological 
duplicate under proliferative culture conditions. Unsupervised clustering using the 
most variable sites across these libraries clearly separated GNS from NS cells (Fig. 
1B). As expected, given patient heterogeneity, GNS cells had a greater diversity of 
chromatin profiles than NS cells. Interestingly, the regions identified as more 
accessible in GNS versus NS cells were enriched in the forkhead box motif and HMG 
box motif which are bound by FOX and SOX factors, respectively (Fig. 1C). These 
data suggest that increased FOXG1 protein levels and FOX/SOX enriched chromatin 
accessibility sites are a hallmark that distinguishes GNS cells from genetically normal 
NS cells. 
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Loss of FOXG1 sensitises NS cells to astrocyte differentiation cues 
Mouse NS cells are a genetically and experimentally tractable model for 
interrogating self-renewal and differentiation commitment. Replacement of the growth 
factors EGF/FGF-2 with BMP4 results in prompt and uniform cell cycle exit and 
upregulation of astrocyte markers including Gfap and Aqp4 (Fig. 2A-C) (Conti et al. 
2005). We used this culture system to explore the specific and shared functions of 
Foxg1 and Sox2. 
Sox2 has previously been shown be essential for NS cell self-renewal in vitro 
(Gómez-López, et al, 2011). To test whether Foxg1 is required for in vitro self-renewal 
of NS cells we derived a new NS cell line (termed FF) from the subventricular zone of 
a previously reported adult Foxg1flox/flox mouse (Miyoshi and Fishell, 2012) (Fig. S2A). 
Transient transfection with a Cre expression plasmid resulted in biallelic excision of 
the Foxg1 coding locus. Monitoring of the Foxg1 ablated cells over many passages – 
using a GFP reporter of Cre excision – suggested there was no proliferation deficit 
(Fig. S2B). Indeed, we could readily establish clonal Foxg1 mutant NS cell lines (Fig. 
2D). The mutant cells demonstrated no difference in proliferation or marker expression 
when grown in EGF/FGF-2; they also retained astrocyte differentiation potential (Fig. 
S2B-C). However, in response to a combination of BMP4 and reduced amounts of 
EGF/FGF-2, Foxg1-/- cells showed an increased propensity to exit cycle and 
differentiate (Fig. 2E). These data suggest that Foxg1 is dispensable for the 
maintenance of continued NS cell proliferation in vitro. It may be required instead to 
protect cells from differentiation commitment. 
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Overexpression of FOXG1 and SOX2 in adult NS cells suppresses BMP-induced 
astrocyte differentiation 
The high levels of FOXG1 and SOX2 in GBM stem cells may underlie the 
failure of differentiation commitment and unconstrained self-renewal associated with 
these malignancies (Carén et al., 2015). To test the consequences of increased 
FOXG1 and SOX2, we transfected genetically normal adult subependymal zone 
(SEZ)-derived mouse NS cell cultures (ANS4) with a stably integrating PiggyBac 
transposon plasmid carrying a tetracycline-inducible FOXG1-2A-SOX2 expression 
cassette (Fig. 2F). Clonal NS cell lines were generated that responded to doxycycline 
(Dox) treatment by increasing expression of FOXG1 and SOX2 mRNAs in a dose-
dependent manner (Fig. 2F-H). We used the human FOXG1 and SOX2 coding 
sequence, as the major goal was to uncover their roles in human GBM and these are 
each ~97% identical at the protein level to their mouse homologs, with 100% 
homology in the DNA binding domains (Fig. S2D). In parallel, we established inducible 
lines expressing FOXG1 or SOX2 individually, termed F6 and S15, respectively (Fig. 
S2E-F). FOXG1 was expressed as a fusion protein with a V5 epitope tag that enabled 
monitoring of transgene expression. 
We cultured FS3, F6, and S15 cells in self-renewal media (EGF/FGF-2) plus 
BMP4, with or without Dox. Under these conditions, parental ANS4 cells adopt an 
astrocyte morphology and stop proliferating. Dox-induced expression of either FOXG1 
or SOX2 alone had little effect on astrocyte differentiation and cells did not proliferate. 
However, co-expression of both factors restricted the differentiation response, and 
cultures remained proliferative (Fig. 2I-J). These data indicate that overexpression of 
FOXG1 and SOX2 in combination can attenuate the cytostatic effects of BMP-induced 
astrocyte differentiation. 
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Overexpression of FOXG1 and SOX2 in post-mitotic astrocytes triggers de-
differentiation to a proliferative NS cell-like state 
We next explored the functional consequences of forced expression of FOXG1 
and SOX2 in differentiating astrocytes. A quantitative in vitro colony forming assay 
was developed to determine if these factors can trigger cells to re-enter cell cycle and 
de-differentiate to the proliferative NS cell state (Fig. 3A). As a positive control we 
used a previously reported glioma-initiating mouse NS cell line, IENS (Ink4a/ARF 
deletion; EGFRvIII overexpression) (Bachoo et al., 2002; Bruggeman et al., 2007). 
IENS cells express FOXG1 at high levels relative to normal NS cells (ANS4) and are 
highly malignant on transplantation (Supplemental Fig. S1B). 
When parental ANS4 cells are plated at low density (10 cells/mm2) and cultured 
for 24 hours in the presence BMP4 but without the growth factors EGF/FGF-2, all cells 
undergo astrocyte differentiation and are subsequently unable to re-enter cell cycle 
when re-exposed to self-renewal media, as assessed by EdU incorporation; i.e. they 
are post-mitotic and growth factor unresponsive (Fig. 3B and S3A). When returned to 
self-renewal conditions glioma-initiating IENS cells form scattered proliferating NS cell-
like colonies, consistent with a suppression of BMP-induced differentiation (Fig. 3C). 
Dox-induced expression of exogenous FOXG1 and SOX2 in the growth factor 
unresponsive and post-mitotic astrocytes (BMP-treated, FS3 cells) resulted in dose-
dependent colony formation (Fig. 3C), whereas the no Dox-treated controls failed to 
form colonies. The colonies that emerged in Dox-treated plates were rapidly cycling 
and comprised Nestin-high, Gfap-low cells with a characteristic NS cell morphology 
(Fig. 3D). FOXG1/SOX2-induced colonies were typically similar in size to control NS 
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cell colonies (data not shown), and inspection of time-lapse imaging of de-
differentiation revealed doubling times of ~24 hours, which is comparable to parental 
NS cells and suggests cells rapidly adopt a highly proliferative NS cell-like phenotype 
(Fig. S3B and Supplemental Movie 1). Transcriptome profiling of these cells by RNA-
seq identified expression changes compatible with de-differentiation and reacquisition 
of many features of the untreated parental cells grown in EGF/FGF-2 (Fig. 3E), such 
as differentiation potential (Fig. 3F). The de-differentiated cells continued to divide 
upon Dox withdrawal and could be serially passaged; they exhibited a morphology, 
proliferation rates and marker expression similar to the parental FS3 cells 
(Supplemental Fig. S3C-E). They also remained BMP4-responsive and activate Gfap 
(Supplemental Fig. S3F). 
To exclude the possibility that FOXG1/SOX2-induced astrocyte de-
differentiation was limited to in vitro generated astrocytes, we next introduced the 
TET-FOXG1-2A-SOX2 transgene into freshly isolated mouse astrocytes (Fig. 3G). 
Induction of FOXG1 and SOX2 in primary astrocytes contributed to a significant 
increase in NS cell-like colonies when cells were transferred into self-renewal media. 
We conclude that overexpression of FOXG1 and SOX2 in astrocytes reverses 
differentiation, and is sufficient to drive cells to enter cell cycle and acquire a 
proliferative NS cell identity (Fig. 3H). 
  
ChIP-seq identifies FOXG1 binding at core cell cycle and methyltransferase 
target genes 
The in vitro de-differentiation assay provided a tractable system to define  
transcriptional target genes through which FOXG1 and SOX2 operate. Sox2 target 
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genes in mouse neural progenitor cells have been previously defined using ChIP-seq 
(Lodato et al., 2013). Identification of FOXG1 targets has been hindered by the 
limitations of available native antibodies. To overcome this, we performed ChIP-seq in 
NS cells constitutively expressing the V5 epitope-tagged version of FOXG1, which 
remained functional in our earlier dedifferentiation assays (Fig. 3). Two independent 
NS cell lines constitutively overexpressing FOXG1-V5 were generated from ANS4 and 
an independent primary adult SVZ-derived NS cell line. From the V5 ChIP-seq we 
identified 6897 high confidence binding sites shared between these cell lines, and 
motif enrichment analysis confirmed the canonical forkhead motif to be most 
significantly enriched (Fig. 4A). We also found many other neurodevelopmental 
lineage-affiliated TF motifs enriched at these sites, including: bHLH, HMG box (the 
SOX family binding motif) and CTF/NF1 factors (Fig. 4A). These are bound by TFs 
recognised as key components of the core circuit of self-renewal in NS cells (Mateo et 
al., 2015). Genes associated with these peaks were enriched in several notable Gene 
Ontology (GO) categories, including: Notch and TGF-beta signaling, stem cell 
maintenance and methyltransferase/histone methyltransferase function (Fig. S4). 
Mitochondrial GO terms were also identified, consistent with reports of a role for 
FoxG1 in the regulation of mitochondrial function (Pancrazi et al., 2015). 
 We next examined the intersection of newly defined FOXG1 peaks with the 
16683 sites previously reported as bound by Sox2 in cultured mouse neural 
progenitors (Lodato et al., 2013). There was a substantial overlap, with 3856 of the 
6897 FOXG1 peaks also represented in the Sox2 dataset (Fig. 4B). The associated 
set of genes is strongly enriched for GO categories including: Notch signaling, histone 
methyltransferase complex, mitotic cell cycle checkpoint, and stem cell maintenance 
(Fig. 4C). This is consistent with the functional consequences of overexpression of 
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FOXG1/SOX2 – namely, cell cycle re-entry and de-differentiation – and suggests both 
factors may play a role in controlling these processes. 
Binding of a TF alone does not constitute evidence of a functional role in 
regulating the candidate target gene. RNA-seq was therefore performed in order to 
identify a subset of candidate FOXG1/SOX2 regulated loci (Fig. 4D). As anticipated, 
BMP exposure rapidly led to downregulation of Nestin expression and upregulation of 
the astrocyte markers Aqp4 and Gfap. Of note, FOXG1/SOX2 bound targets that 
showed altered expression 4 days after Dox treatment and return to self-renewal 
media (EGF/FGF-2) included core regulators of cell cycle (Plk1, Foxo3, Mycn) and 
epigenetic processes (Dnmt1 and Tet3) (Fig. 4D). Foxo3 expression was one of the 
most significantly upregulated genes after 24 hr of BMP treatment, and was 
downregulated upon treatment with Dox and exposure to EGF/FGF-2. Foxo3 is a well-
established negative regulator of cell proliferation downstream of the PI3K signaling 
pathway. FOXG1/SOX2 bound regions included the proximal promoter and a 
conserved intronic element harboring multiple motifs for SOX and FOX (Fig. 5C). We 
therefore pursued this as a candidate functionally important target. 
 
Transcriptional repression of Foxo3 by FOXG1/SOX2 removes a barrier to 
astrocyte cell cycle re-entry  
Foxo3 has an established role in NS cell homeostasis and quiescence (Webb 
et al., 2013), and a recent study suggests it is directly regulated by Foxg1 (Vezzali et 
al., 2016). Our own RNA-seq data indicated a rapid upregulation of Foxo3 mRNA 
following BMP-induced astrocyte differentiation (Fig. 4D). Levels of Foxo3 mRNA are 
reduced following addition of Dox and a switch to NS cell media (Figs. 4D and 5A). 
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ICC for Foxo3 protein confirmed upregulation and nuclear translocation following BMP 
treatment (Fig. 5B). ChIP-seq data indicated binding of both FOXG1 and SOX2 at a 
highly conserved intronic element (CIE) within Foxo3 (Fig. 5C). This region contains 
multiple repeats of the sequence AAACA, which comprises part of binding motifs for 
FOX and SOX transcription factors in NS cells (Lodato et al., 2013). 
To directly test the functional significance of binding at the Foxo3 CIE we took 
advantage of CRISPR/Cas9 genome editing, which we have optimized for mouse and 
human NS cells (Bressan et al., 2017). Using a pair of guide RNAs (gRNAs) we 
deleted the 780 bp Foxg1/Sox2-bound CIE in FOXG1/SOX2 overexpressing FS3 cells 
(Fig. 5C). Sub-clones were identified in which both alleles were disrupted (Fig. 5D). 
Deletion of this element led to increased levels of Foxo3 mRNA expression under self-
renewal conditions (EGF/FGF-2) (Fig. 5E), and proliferation of this line was marginally 
slower (data not shown). Importantly, these cells were now unable to undergo de-
differentiation in response to FOXG1/SOX2 overexpression (Fig. 5F). We surmise that 
this regulatory element is critical in enabling FOXG1/SOX2 to repress Foxo3 
expression, thereby removing a critical blockade to cell cycle re-entry.  
To confirm the potential relevance of these findings to human GBM, we 
performed ChIP-seq for FOXG1 in four independent human GNS cell lines (G7, G14, 
G25 and G166) using an antibody against endogenous FOXG1. Although less specific 
than V5 ChIP, we identified a total of 7499 peaks and noted strong enrichment for the 
forkhead box and related motifs (Fig. S5A). These data showed that FOXG1 was 
bound to the FOXO3 CIE (Fig. S5B).  
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Reacquisition of the proliferative NS cell state can be achieved by combined 
loss of Foxo3 and alterations to DNA methylation 
To test the consequences of Foxo3 deletion, we excised exon 2 of Foxo3 in 
FS3 cells using CRISPR/Cas9-assisted gene targeting (Bressan et al., 2017). Biallelic 
mutant lines were generated through simultaneous replacement of one Foxo3 allele 
with an EF1a-Puromycin resistance cassette and insertion-deletion (indel) mutations 
on the remaining allele (Fig. S5C). Foxo3 protein was undetectable in a clonal line that 
contained a frameshift indel mutation and generated a nonsense product (FOD3; Fig. 
5G). These FOD3 Foxo3-/- mutant cells retained a similar responsiveness to BMP 
treatment as their parental cells, with concomitant upregulation of astrocyte markers 
including Gfap and acquisition of the characteristic morphology (data not shown). 
However, in contrast to parental controls which exited cell cycle, Foxo3 mutant cells 
proliferated slowly on re-exposure to EGF/FGF-2 without Dox (doubling time of ~6 
days; Fig. 5H). Thus, Foxo3 ablation sensitises astrocytes to growth factors and 
relieves a barrier to cell cycle re-entry. Importantly, however, these cells did not fully 
de-differentiate and retained Gfap expression (Fig. 5H-J). They remained slow-cycling. 
We conclude that cell cycle entry and differentiation status are uncoupled in the 
context of Foxo3 deletion. Additional target genes are therefore required to trigger de-
differentiation and rapid proliferation. 
We previously reported that human GBM stem cells fail to undergo terminal 
differentiation commitment and have aberrant DNA methylation patterns in response 
to BMP treatment (Carén et al., 2015). Shared transcriptional targets of FOXG1/SOX2 
included several regulators of DNA and histone methylation. These genes represent 
clear candidates that might be involved in destabilizing astrocyte differentiation. 
Inhibition of DNA methyltransferase (Dnmt) activity by the nucleoside analogue 5-
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azacytidine (Aza) has been reported to facilitate iPS cell reprogramming (Mikkelsen et 
al., 2008). We therefore hypothesized that Dnmt inhibition by 5-Aza might enable de-
differentiation by interfering with establishment or maintenance of the DNA 
methylation profile in differentiating astrocytes. Indeed, either 5-Aza or ascorbic acid 
(a co-factor for Tet proteins), could trigger increased proliferation in populations of 
Foxo3 mutant astrocytes (Fig. S5D).  This was quantified for 5-Aza using colony 
formation assays for the slow cycling BMP-treated Foxo3 mutants (FOD3). Strikingly, 
the combination of Aza treatment with Foxo3 deletion resulted in emergence of rapid-
cycling populations forming similar numbers of Nestin-positive colonies to the Dox-
treated FS3 cultures (Fig. 5H-J). Thus, Aza in combination with loss of Foxo3 can 
phenocopy the effects of FOXG1/SOX2 induction. Resetting of DNA methylation 
patterns that are acquired during astrocyte differentiation may therefore be a critical 
feature of FOXG1/SOX2 reprogramming activity. 
 
FOXG1 overexpression affects multiple regulators of DNA methylation to 
facilitate de-differentiation 
We next investigated the effect of forced expression of higher levels of FOXG1 or 
SOX2 alone using the F6 and S15 lines, respectively (Fig. S2E-F). Each of these lines 
enabled higher levels of each individual factor to be expressed in differentiating 
astrocytes. High levels of induction of FOXG1 alone, but not SOX2, was sufficient to 
drive efficient colony formation in two independent FOXG1 inducible lines (F6 and 
F11) (Fig. 6A-B). The resulting de-differentiated cells displayed morphology, 
proliferation kinetics and marker expression similar to the parental line and responded 
to BMP-induced differentiation (Fig. S6A and S6C-E). RNA-seq confirmed that these 
cultures were re-acquiring NS cell-like transcriptional signatures and many of the 
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activated genes included FOXG1/SOX2 bound genes (Fig. 6C). We confirmed by 
RNA-seq and qRT-PCR that there is a significant increase in expression of Dnmt1, 
Dnmt3b and Tet3 following increased FOXG1 expression (Fig. 6D and S6B). Thus, 
the excessively high levels of expression of FOXG1 in GBM may specifically operate 
in limiting differentiation (Fig. 6).  
 
DNA methylation changes at polycomb target genes, including Foxo3, occur 
during astrocyte differentiation 
To define the DNA methylation changes that accompany BMP-induced astrocyte 
differentiation we performed reduced representation bilsulfite sequencing (RRBS). 
Analysis of the resulting methylation profiles identified a total of 3231 significantly 
Differentially Methylated Regions (DMRs) after 24 hr or 10 days of BMP-induced 
differentiation (756 with reduced methylation and 2475 with increased methylation). 
These DMRs where significantly enriched near developmental TFs (Fig. S6F). 
Developmental TFs are known to be regulated by polycomb repressive complexes; 
indeed, BMP-induced differentiation DMRs were enriched near polycomb repressive 
complex target genes previously reported in mouse NS cells, embryonic stem cells 
and brain (Fig. 6E) (Meissner et al., 2008). This included methylation changes at the 
promoter of Foxo3 close to a Foxg1 binding site (Fig. 6F). These analyses suggest 
that DNA methylation changes occur at developmental TFs during astrocyte 
differentiation and that FOXG1 may help in reconfiguring these during de-
differentiation, via its control of multiple regulators of DNA methylation.  
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Genetic ablation of FOXG1 in human GNS cells does not affect in vitro 
proliferation but SOX2 is essential 
Previous studies using shRNA knockdown of FOXG1 have suggested an 
important role in promoting tumour growth (Verginelli et al., 2013). CRISPR/Cas9 
provides new opportunities for decisive functional genetic studies in primary human 
GBM stem cells. Using recently optimised protocols (Bressan et al., 2017), we next 
performed gene targeting via homologous recombination to delete FOXG1 in human 
primary GNS cells (G7) (Fig. S7A). One of the resulting clonal lines (G7-A1) 
harboured a 23 bp frameshift insertion at the second allele and demonstrated loss of 
FOXG1 protein by immunoblotting (Fig. 7A and S7A). In contrast to previously 
reported findings using tumour sphere models, we found no discernible effect of 
FOXG1 ablation on proliferation rates of GNS cells in vitro (Fig. 7B). 
We next compared the FOXG1 loss-of-function phenotype with SOX2 loss in 
G7 cells. Previous studies have suggested that Sox2 is required for self-renewal of 
forebrain NS cells: homozygous knockout by conditional deletion or CRISPR/Cas9 
targeting is incompatible with colony formation (Bressan et al., 2017; Gómez-López et 
al., 2011). Here, CRISPR/Cas9 was used to mutate the single coding exon of SOX2 
(Fig. S7B). We were unable to recover expandable SOX2 mutant clones, suggesting 
these may have a proliferation defect. The proportion of SOX2 negative cells were 
tracked in the primary transfected population over time by ICC (Fig. S7C-E). ~25% of 
mutant cells were detectable in the transfected population at day 7; however, by day 
14 and day 42 this subpopulation had dropped to ~18% and <1% of the population, 
respectively. Co-culture with the non-deleted wild-type cells clearly could not rescue 
the proliferation defect. We conclude that loss of SOX2 ablates the proliferative 
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capacity of patient-derived GBM cells in a cell autonomous manner. This contrasts 
with FOXG1, which is dispensable for in vitro NS cell proliferation. 
 
FOXG1 mutant human GNS cells are sensitised to cytostatic signals in vivo and 
upregulate FOXO3 
To test the consequences of FOXG1 loss in vivo we transplanted cells 
orthotopically into the brains of immunocompromised mice. A GFP reporter construct 
was inserted at the safe harbour AAVS1 locus, in both parental control cells and the 
FOXG1-/- clone to enable monitoring of cells following xenotransplantation. Consistent 
with the previously reported shRNA knockdown results (Verginelli et al., 2013), we 
saw a failure of the FOXG1-/- G7-A cells to form tumours on transplantation into 
immunocompromised mice (Fig. 7C; n=4). We hypothesised that FOXG1 is able to 
protect cells from pro-differentiation signals that would trigger exit from the cell cycle in 
vivo. 
Our findings in mouse NS cells suggested that FOXG1 operates in part by 
helping repress FOXO3 and this could be a key effector of its function by limiting 
astrocyte differentiation. We therefore assessed expression of GFAP and FOXO3 in 
the FOXG1 knockout cells following transplantation in vivo. The transplanted cells 
were present at the injection site and these were found to express high levels of 
GFAP and FOXO3 and low levels of Ki67 compared to wild type controls. They also, 
displayed morphological features of differentiated ‘star shaped’ astrocytes (Fig. 7D-H; 
n=4). This indicates that FOXG1 is required in GBM stem cells to sustain GNS cell 
growth in vivo. In conclusion, we find that SOX2 is essential for continued proliferation 
of GBM stem cells, while FOXG1 is not. However, increased levels of FOXG1 
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safeguard the stem cell state from pro-differentiation cues encountered outside the 
endogenous SVZ niche. This restriction of differentiation commitment is mediated at 
least in part through repression of negative regulators of proliferation such as FOXO3. 
(Fig. 7I).  
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Discussion 
There are important conceptual and mechanistic similarities between cellular 
transformation in human cancers and cellular reprogramming (Suvà et al., 2013). 
FOXG1 and SOX2 are key regulators of forebrain neural progenitor fate and are 
known reprogramming factors (Lujan et al., 2012). Here we have demonstrated that 
high FOXG1 and SOX2 levels, a consistent feature of GNS cells, are functionally 
important in driving a highly proliferative, growth factor responsive, radial glia-like NS 
cell state. These master regulators operate through transcriptional control of various 
stem cell-associated pathways, most notably cell cycle and epigenetic regulators. 
Cancer stem cells therefore deploy overexpression of key lineage-affiliated TFs as a 
mechanism to fuel their self-renewal the same strategy used by stem cell biologists in 
experimental reprogramming. 
FOXG1 is consistently upregulated across all GNS cells we assessed. Using 
ATAC-seq profiling of human GNS and NS cells, we identified an enrichment of open 
regions containing many neurodevelopmental TF motifs, including binding sites of 
SOX and FOX transcription factor families. This supported our hypothesis that 
increased levels of FOXG1 and SOX2 might be important in driving GBM cell self-
renewal and is consistent with the known roles of these factors during development of 
the mammalian forebrain (Xuan et al., 1995).  
We initially explored Foxg1 loss of function using a new conditional NS cell line. 
Mutant cells become sensitized to differentiation cues, but surprisingly, there was no 
proliferative defect in vitro. This contrasts with loss of Sox2, which has previously been 
shown to be a critical factor for proliferation of mouse NS cells. This suggested to us 
that the gain of function phenotype for Foxg1 is more critical, and its role might be 
specifically in limiting terminal differentiation commitment or driving de-differentiation. 
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A quantitative colony formation assay was developed to explore the consequences of 
increased expression of human FOXG1 and SOX2 in de-differentiating astrocytes, 
thereby mimicking the increased levels of FOXG1 seen in GBMs. We didn’t observe 
increased levels of SOX2 protein in GNS cells, compared to NS cells. However, unlike 
FOXG1, SOX2 is amplified in GBM. It is possible that the levels of SOX2 in NS cells 
are already saturating in vitro. We find that NS cells plated at low density and treated 
with BMP4 for 24 hours exit cell cycle with acquisition of astrocyte morphology and 
markers. Quiescent NS cells in vivo express Gfap. So are we modelling the transition 
from quiescence to reactivation/proliferation, as opposed to terminal differentiation to 
de-differentiation? We believe this is less likely, as we could induce NS cell colony 
formation by FOXG1/SOX2 induction when using fresh primary postnatal astrocyte 
preparations. Furthermore, we have recently found low density BMP treated 
astrocytes have reduced levels of quiescent stem cell astrocyte markers (data not 
shown). A key functional criterion for distinguishing quiescent astrocytes and the 
differentiating astrocytes is that the latter cannot be driven into cycle when re-exposed 
to EGF/FGF-2. Thus, we view our assay as a de-differentiation response. 
  Our ChIP-seq data for FOXG1 and the intersection with SOX2-bound sites 
suggested that these factors have common target genes, including both important 
core cell cycle and epigenetic regulators. However, we have found no indication of 
physical interaction between SOX2 and FOXG1 using protein co-immunoprecipitation 
(data not shown). This is consistent with characterized SOX2 protein partner analysis 
in mouse NS cells (Engelen et al., 2011). Rather, it seems likely that FOXG1 and 
SOX2 are cooperating indirectly at the gene regulatory network level. Defining their 
shared transcriptional targets is therefore valuable and may help define new 
therapeutic targets. 
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Exposure to Dox and EGF/FGF-2 triggered a relatively rapid emergence of 
proliferating colonies, whether from NS cell-derived in vitro generated astrocytes, or 
astrocytes from primary cultures. Inspection of this response by time-lapse imaging 
together with the sizes of resulting colonies suggested that cell cycle re-entry was an 
early event. We recognize that multiple targets will contribute to the potency of 
FOXG1/SOX2 activity, and we searched for those candidates that might have a major 
contribution. Foxo3, which has an established role in NS cell homeostasis and 
quiescence, emerged as a functionally important transcriptional target of 
FOXG1/SOX2. This finding is consistent with Foxo3 as a transcriptional target of 
FOXG1 during telencephalic development (Vezzali et al., 2016). FOXO3 activity is 
also known to be affected by interaction with FOXG1 at the protein level (Seoane et 
al., 2004); FOXG1 therefore exerts a dual inhibition of FOXO3 activity, at the protein-
protein level and through transcriptional suppression. We used CRISPR/Cas9 genetic 
ablation to confirm FOXG1 repression of Foxo3 at the transcriptional level. 
Importantly, in the absence of the FoxG1-bound repressive element in the Foxo3 
intron, NS cells could no longer respond to Dox. Transcriptional repression of Foxo3 
through this site may therefore be the primary mechanism of control by FoxG1, with 
the sequestration through protein-protein interaction being an added layer of 
regulatory control. 
Foxo3 ablation removes a barrier to cell cycle re-entry; however, the mutant cells 
retained astrocyte morphology, high GFAP expression and displayed slow 
proliferation kinetics on restoration of growth factors following BMP treatment. Foxo3 
repression alone is therefore insufficient to trigger full de-differentiation to an NS cell-
like state. Additional targets must exist. Given the prominence of methyltransferase 
and histone methyltransferase complexes in Gene Ontology analysis of the 
FOXG1/SOX2 bound regions, we explored whether resetting of DNA methylation 
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patterns could remove a barrier to de-differentiation. This proved to be the case, as a 
short 24 hr pulse of a low dose of Aza (a nucleoside analogue which inhibits DNA 
methyltransferase activity) or ascorbic acid (co-factor of the TET family of enzymes 
which trigger DNA demethylation) was sufficient to stimulate rapid proliferation of 
Foxo3 mutant cells. Thus, the effects of FOXG1/SOX2 overexpression can be 
phenocopied by removal of Foxo3 and reconfiguration of DNA methylation patterns. 
Multiple regulators of DNA methylation were bound by FOXG1, including Tet3, 
Dnmt3b and Dnmt1. These displayed changes in expression upon Dox treatment in 
FOXG1 alone overexpressing cells (F6).  
DNA methylation profiling using RRBS identified significant methylation 
changes in astrocytes following 24 hr BMP4 treatment that were heavily enriched for 
polycomb target genes, including Foxo3. Unfortunately, as only a subpopulation of the 
cells undergo de-differentiation following re-exposure to growth factors and addition of 
Dox, we were unable to identify any significant changes in methylation after 4 days 
(data not shown). Future studies will require isolation/enrichment for the earliest de-
differentiating cells to define the specific link between key sites of methylation 
changes and FOXG1 binding. Tet3 is a clear candidate that might impact the stability 
of the methylome in differentiating astrocytes. Our current data supports a model in 
which high levels of FOXG1/SOX2 have at least two complementary activities: 
stimulation of core cell cycle regulators and triggering of epigenetic resetting to drive 
post-mitotic astrocytes into the more immature radial glial-like NS cell state (Fig. 7I). 
Further definition of the downstream targets of these factors might uncover ‘druggable’ 
targets, and guide rational combination therapy strategies. 
Not all astrocytes are able to respond to FOXG1/SOX2. It is possible that 
additional factors or signaling pathway manipulations could improve efficiency. There 
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might also be some stochastic element to triggering de-differentiation, as is the case 
with iPS cell reprogramming (Buganim et al., 2012). Other noteworthy annotated gene 
sets that we identified via ChIP-seq analysis included mitochondrial function, Notch 
and Wnt/Beta catenin signaling. Many of these have been implicated in the growth of 
GBMs and further studies will be needed to define whether these can enhance de-
differentiation. 
Using CRISPR/Cas9 gene targeting we were able to genetically ablate FOXG1 
in primary human GBM stem cells. FOXG1 is dispensable for in vitro NS cell 
proliferation when cultured in adherent conditions with EGF/FGF-2. This seemingly 
contradicts previous shRNA knockdown studies that concluded FOXG1 is required to 
sustain proliferation (Verginelli et al., 2013). However, Verginelli et al. assayed 
proliferation using tumour spheres, a condition in which spontaneous differentiation 
can occur. Thus the discrepancy is likely explained by differences in culture regime. 
These findings are also consistent with the fact that we can routinely derive NS cell 
lines from different regions of the developing nervous system (midbrain, hindbrain, 
spinal cord) that express FoxG1 neither in vivo nor in vitro. Thus FOXG1 is not an 
essential cell cycle driver in NS cells; rather, it is required to protect cells from pro-
differentiation cues and can trigger the transition out of the non-proliferative state. 
Previous studies have explored the core transcriptional circuits that might be 
exploited by GBM stem cells. A reprogramming cocktail incorporating SOX2, OLIG2 
and POU3F2 has been used to reinstate tumorigenicity in 'differentiated' glioblastoma 
cells (Suvà et al. 2014) and this network was generated by focusing on TFs 
differentially expressed between GBM stem cells and serum-induced differentiating 
progeny. FOXG1 was not among the factors comprising the core transcriptional circuit 
identified in these studies. However, a recent study by the Barres laboratory (Zhang et 
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al., 2016) has identified genes differentially expressed betweeen immature fetal 
astrocytes from post-mitotic adult cortical astrocytes. FOXG1 is indeed one of the 
most differentially expressed genes (Fig. S7F). We speculate that upregulation of 
FOXG1 expression is a critical event in the emergence of GBM, occurring either early 
in tumorigenesis to produce primary glioblastoma, or later resulting in secondary 
transformation of a low grade glioma. In keeping with this, we have found variable 
FOXG1 expression in a panel of tumour lines derived from WHO Grade II and Grade 
III gliomas (data not shown).  
In conclusion, we show that elevated FOXG1 plays a functionally important role 
in limiting differentiation commitment, whereas SOX2 is required to sustain NS and 
GNS cell proliferation. When co-expressed these two factors drive self-renewal and 
enforce a proliferative radial glial-like NS cell state. Although we find no evidence of a 
protein level interaction between these factors, they share multiple core cell cycle and 
epigenetic regulatory targets. Our findings highlight the increasing evidence in support 
of a critical role for neurodevelopmental transcription factors in driving unconstrained 
self-renewal in GBM. 
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Experimental procedures 
Cell culture 
Mouse and human neural stem (NS) and glioma neural stem (GNS) cell lines were 
derived from adult subventricular zone, fetal cortex or primary glioblastoma specimens 
as previously described (Conti et al. 2005; Sun et al. 2008). Established lines were 
cultured in serum-free basal medium supplemented with N2 and B27 (Life 
Technologies), laminin (Sigma, 1mg/ml) and growth factors EGF and FGF-2 
(Peprotech, 10 ng/ml). Medium was changed every 3 days and cells split typically 
once per week after dissociation with Accutase solution (Sigma) and centrifugation.  
BMP treatment comprised plating dissociated NS cells at low density (10 cells/mm2) in 
medium supplemented with 10 ng/ml BMP4 (Peprotech) in place of EGF/FGF-2. After 
24 hours this was replaced by standard growth medium containing EGF/FGF-2. 
Colonies were stained with ethidium bromide and visualized under UV light. 
IENS cells, previously described (Bruggeman et al., 2007), were kindly provided by M. 
Van Lohuizen (NKA, Amsterdam). A table detailing the mouse NS cell line derivatives 
established here and a summary of their differentiation/de-differentiation 
characteristics is provided (Supplemental Table 1). Growth curves were generated 
using an IncuCyte live cell imaging system.  
Primary mouse astrocyte cultures were prepared from the trypsin-digested cortical 
plate tissue of P3 mice cortices (strain MF1), according to established protocols 
(Schildge et al., 2013), including shake-off after one week to remove contaminating 
microglia and progenitor cells.  
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Derivation of stable transgenic and knockout cell lines 
One million cells were transfected with the Amaxa Nucleofector system, using either 
the X005 pulse protocol (human cells) or T-030 protocol (mouse cells). 
For inducible transgene overexpression, a total of 6 μg DNA was supplied comprising 
piggyBac transposase pBASE, pCAG-rtTA(Tet3G) and pDEST-TetOn vector in 1:1:2 
ratios. For CRISPR targeting, guide RNAs (x2), targeting vector (where appropriate) 
and Cas9 nickase were transfected in a 1:1:1:2 ratio.  
Cells were plated in 10 cm dishes, with doxycycyline added after 24 hours where 
appropriate, and selection commenced 48 hours post-transfection using blasticidin (5 
μg/ml), puromycin (1 μg/ml) or hygromycin (100 μg/ml). Each of these antibiotics 
produced uniform cell death within 7 days in untransfected mock controls (both human 
NS and GNS cells). 
G7 primary human GNS cells were transfected with Cas9 nickase, guide RNAs 
corresponding to the forkhead domain of the FOXG1 locus, and a targeting vector 
comprising an EF1a-PURO antibiotic resistance cassette flanked by 1 kb homology 
arms specific for the locus. 
Immunocytochemistry 
Cells were washed with PBS and fixed using 4% paraformaldehyde for 10 min at room 
temperature. Samples were incubated overnight with primary antibodies in blocking 
solution (PBST +3% goat serum and 1% BSA) followed by incubation with appropriate 
secondary antibodies and 4',6-diamidino-2-phenylindole (DAPI). Images were 
obtained using the Zeiss Observer Z1 microscope and AxioVision software, or the 
PerkinElmer Operetta high content imaging system and Harmony software. 
Transplanted mice brains were harvested, sectioned into 30 μm slices using a 
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vibratome, stained using IHC as free-floating staining, and imaged using a Leica SP8 
confocal microscope. 
The following primary antibodies were used: Olig2 (1:100, Millipore), V5 tag (1:1000, 
eBioscience), Sox2 (1:50, R&D Systems), mNestin (DSHB, 1:10), hNestin (1:500, 
R&D Systems), FOXG1 (1:3, hybridoma clone 17B12), FOXO3 (1:800, CST), GFAP 
(1:1000, Sigma), S100 (1:100, DAKO), Stem121 (1:500, StemCells), BLBP (1:200, 
Santa Cruz) and Ki67 (1:500, Lab Vision). EdU incorporation assays were performed 
as previously described (Caren et al., 2015). 
Western immunoblotting 
Immunoblotting was performed using standard protocols. Antibodies were diluted in 
5% milk powder in PBS triton 0.1%, and protein detection was carried out with HRP-
coupled secondary antibodies and X-ray films. The following primary antibodies were 
used: FOXG1 (1:15, hybridoma clone 17B12), SOX2 (1:400, R&D Systems), OLIG2 
(1:800, Millipore) GAPDH (1:1000; GenTex), and V5 tag (1:1000; eBioscience). 
qRT-PCR and Low Density Arrays  
RNA extraction was performed using the Qiagen RNeasy Plus Mini spin column kit, 
eluting in 50 μl RNase free water and using an additional DNase step. RNA 
concentration was determined using the Qubit RNA High Sensitivity kit (Life 
Technologies). Reverse transcription was performed using Invitrogen Superscript III kit 
according to manufacturers’ instructions. TaqMan qPCR and TaqMan Low Density 
Array (TLDA) card assays were performed using TaqMan Universal PCR Master Mix 
and assays (Applied Biosystems) according to the manufacturer's guidelines. Results 
were normalised to the housekeeping gene, Gapdh. The following TaqMan assays 
were used: mGapdh (Mm99999915_g1), mFoxG1 (Mm02059886_s1), mFoxo3 
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(Mm01185722_m1), mGfap (Mm01253033_m1), mAqp4 (Mm00802131_m1), 
mS100b (Mm00485897_m1), mNestin (Mm00450205_m1), mOlig2 
(Mm01210556_m1), mBlbp (Fabp7) (Mm00445225_m1), mSox2 (Mm03053810_s1), 
mDnmt1 (Mm01151063_m1), mDnmt3b (Mm01240113_m1), mTet3 
(Mm00805756_m1) and hGAPDH (Hs02758991_g1). 
RNA-seq library construction 
RNA sequencing libraries were prepared from 100 ng mRNA extracted using Qiagen 
RNeasy kits. Library prep was conducted using NEBNext mRNA reagents (E6100) 
and multiplex indices for Illumina (E7335). 
ChIP-seq library construction 
Chromatin was prepared and immunoprecipitation undertaken according to protocols 
previously described (Hadjur et al., 2009). Sonication was performed in 0.7% SDS 
using a Diagenode Bioruptor (max power 30 seconds on, 30 seconds off, 45 minutes). 
Pulldown was undertaken using Dynabead protein G sepharose beads (Thermo 
Scientific) conjugated with 10 μl of ChIP-grade antibody (anti-FoxG1 Abcam Ab18259; 
anti-V5 Abcam Ab15828) diluted in 250 μl buffer. 
ATAC-seq library construction 
ATAC-seq libraries were prepared using Illumina Nextera reagents as described 
(Buenrostro et al., 2013), with PCR amplification and indexing using published 
sequencing adapter primer sequences supplied as oligonucleotides (Sigma) 
(Buenrostro et al., 2013). 
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ChIP-seq data analysis 
Filtered read files were imported to the Galaxy web-based analysis portal. Within 
Galaxy, the files were parsed into Sanger FastQ format, then each read was truncated 
from 100 base pairs to 55 (base pairs 10-65 of the original read). The read files were 
each mapped to the mouse genome (mm10 assembly) using Bowtie conFig.d with 
default parameters. The resulting BAM alignment files were merged into a single file, 
and peak calling was performed using the MACS 2.0 algorithm. Galaxy was also used 
to determine motif enrichment (SeqPos Motif tool), and the Stanford Genomic Regions 
of Enrichment Annotations Tool (GREAT version 3.0.0) was used for target gene and 
ontology analysis. 
ATAC-seq data analysis 
ATAC-seq data was imported, normalised and compared as described previously 
(Carén et al, 2015), with the exception of motif analysis which was applied to GNS 
enriched loci using all accessible chromatin sequences as a control. Heatmaps were 
generated from CQN normalised data (Hansen et al., 2012) using the Euclidean 
distance metric and Ward's method for clustering the rows. 
Reduced Representation Bisulfite Sequencing library preparation 
gDNA was isolated from F6 cells using MasterPure complete DNA purification kit 
(Epicentre) from three independent experiments and concentrated with the TM-5 DNA 
Clean and Concentrator kit (Zymo Research) before being quantified by Qubit dsDNA 
BR assay and Nanodrop. 85 ng of each purified DNA sample was processed using 
the Ovation RRBS Methyl-Seq System kit (NuGEN Technologies). 0.5 ng of 
unmethylated phage λ DNA was spiked in to each sample to allow assessment of 
bisulfite-conversion efficiency. Briefly, the methylation-insensitive restriction enzyme 
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MspI was used to digest the gDNA and digested fragments were ligated to adapters. 
Adapter-ligated fragments were then repaired before bisulfite- conversion with the EZ 
DNA Methylation-Lightning Kit (Zymo Research). Bisulfite-treated adapter-ligated 
fragments were amplified by PCR (15 cycles) and purified using Agencourt 
RNAClean® XP beads. Libraries were quantified using the Qubit dsDNA HS assay 
and assessed for size and quality using the Agilent Bioanalyser DNA HS kit. 
Sequencing was performed using the NextSeq 500/550 High-Output v2 Kit (150 
cycles) (Illumina) on the NextSeq 550 platform. Libraries were combined into 
equimolar pools and run across four flow cells. Library preparation and sequencing 
was performed at the Edinburgh Clinical Research Facility. 
 
Intracranial xenotransplantation 
Transplants were performed as described previously (Pollard et al., 2009). Briefly, we 
used a stereotaxic frame to inject 100K cells in 1 μl into the striatum of adult NSG 
immunocompromised mice (aged 4-8 weeks). Co-ordinates were 1 mm anterior and 2 
mm lateral to the Bregma, and 2.5 mm deep.  
 
Author Contributions 
Conceptualization, H.B. and S.M.P; Methodology, P.B. H.B, R.B., S.Go., S.Ga, V.F, 
D.S.; Formal Analysis, H.B., E.J, D.S; Investigation, H.B., E.J., M.M., K.F., R.B., C.B., 
V.G., S.Go., S.Ga, C.E.; Writing – Original Draft, H.B, S.P.; Visualization, H.B., E.J., 
S.M.P; Supervision, S.M.P, P.B; Project Administration, H.B., S.M.P.; Funding 
Acquisition, H.B, P.B., S.M.P. 
 
32 
Acknowledgements 
H.B was supported by a Wellcome Trust Clinician Research Training Fellowship. E.J. 
was supported by the BBSRC. M.M is supported by an EMBO training fellowship. K.F 
is supported by a studentship from Cancer Research UK (A19680). R.B.B is 
supported by a studentship from the Science Without Borders Program (CAPES, 
Brazil). DS is a Cancer Research UK Career Development Fellow (Ref: 
C47648/A20837) and work in his lab is also supported by an MRC University Grant to 
the MRC Human Genetics Unit. S.M.P is a Cancer research UK Senior Research 
Fellow (A17368). We thank Gillian Morrison and Keisuke Kaji for helpful comments on 
the manuscript. We thank Richard Clark at the Edinburgh Clinical Research Facility for 
conducting the RRBS and helpful discussion on its data analysis.  
33 
References 
Alonso, M.M., Diez-Valle, R., Manterola, L., Rubio, A., Liu, D., Cortes-Santiago, N., 
Urquiza, L., Jauregi, P., Lopez de Munain, A., Sampron, N., Aramburu, A., Tejada-
Solís, S., Vicente, C., Odero, M.D., Bandrés, E., García-Foncillas, J., Idoate, M.A., 
Lang, F.F., Fueyo, J., Gomez-Manzano, C., 2011. Genetic and epigenetic 
modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. 
PLoS ONE 6, e26740. doi:10.1371/journal.pone.0026740 
Arnold, K., Sarkar, A., Yram, M.A., Polo, J.M., Bronson, R., Sengupta, S., Seandel, 
M., Geijsen, N., Hochedlinger, K., 2011. Sox2(+) adult stem and progenitor cells 
are important for tissue regeneration and survival of mice. Cell Stem Cell 9, 317–
329. doi:10.1016/j.stem.2011.09.001 
Avilion, A.A., Nicolis, S.K., Pevny, L.H., Perez, L., Vivian, N., Lovell-Badge, R., 2003. 
Multipotent cell lineages in early mouse development depend on SOX2 function. 
Genes Dev. 17, 126–140. doi:10.1101/gad.224503 
Bachoo, R.M., Maher, E.A., Ligon, K.L., Sharpless, N.E., Chan, S.S., You, M.J., Tang, 
Y., DeFrances, J., Stover, E., Weissleder, R., Rowitch, D.H., Louis, D.N., DePinho, 
R.A., 2002. Epidermal growth factor receptor andInk4a/Arf:Convergent 
mechanisms governing terminal differentiation and transformation along the neural 
stem cell to astrocyte axis. Cancer Cell 1, 269–277. doi:10.1016/S1535-
6108(02)00046-6 
Brennan, C.W., Verhaak, R.G.W., McKenna, A., Campos, B., Noushmehr, H., Salama, 
S.R., Zheng, S., Chakravarty, D., Sanborn, J.Z., Berman, S.H., Beroukhim, R., 
Bernard, B., Wu, C.-J., Genovese, G., Shmulevich, I., Barnholtz-Sloan, J., Zou, L., 
Vegesna, R., Shukla, S.A., Ciriello, G., Yung, W.K., Zhang, W., Sougnez, C., 
Mikkelsen, T., Aldape, K., Bigner, D.D., Van Meir, E.G., Prados, M., Sloan, A., 
Black, K.L., Eschbacher, J., Finocchiaro, G., Friedman, W., Andrews, D.W., Guha, 
A., Iacocca, M., O’Neill, B.P., Foltz, G., Myers, J., Weisenberger, D.J., Penny, R., 
Kucherlapati, R., Perou, C.M., Hayes, D.N., Gibbs, R., Marra, M., Mills, G.B., 
Lander, E., Spellman, P., Wilson, R., Sander, C., Weinstein, J., Meyerson, M., 
Gabriel, S., Laird, P.W., Haussler, D., Getz, G., Chin, L., Network, T.R., Benz, C., 
Barnholtz-Sloan, J., Barrett, W., Ostrom, Q., Wolinsky, Y., Black, K.L., Bose, B., 
Boulos, P.T., Boulos, M., Brown, J., Czerinski, C., Eppley, M., Iacocca, M., 
Kempista, T., Kitko, T., Koyfman, Y., Rabeno, B., Rastogi, P., Sugarman, M., 
Swanson, P., Yalamanchii, K., Otey, I.P., Liu, Y.S., Xiao, Y., Auman, J.T., Chen, 
P.-C., Hadjipanayis, A., Lee, E., Lee, S., Park, P.J., Seidman, J., Yang, L., 
Kucherlapati, R., Kalkanis, S., Poisson, L.M., Raghunathan, A., Scarpace, L., 
Bernard, B., Bressler, R., Eakin, A., Iype, L., Kreisberg, R.B., Leinonen, K., 
Reynolds, S., Rovira, H., Thorsson, V., Shmulevich, I., Annala, M.J., Penny, R., 
Paulauskis, J., Curley, E., Hatfield, M., Mallery, D., Morris, S., Shelton, T., Shelton, 
C., Sherman, M., Yena, P., Cuppini, L., Dimeco, F., Eoli, M., Maderna, E., Pollo, 
B., Saini, M., Balu, S., Hoadley, K.A., Li, L., Miller, C.R., Shi, Y., Topal, M.D., Wu, 
J., Dunn, G., Giannini, C., O'Neill, B.P., Aksoy, B.A., Antipin, Y., Borsu, L., 
Berman, S.H., Cerami, E., Chakravarty, D., Ciriello, G., Gao, J., Gross, B., 
Jacobsen, A., Ladanyi, M., Lash, A., Liang, Y., Reva, B., Sander, C., Schultz, N., 
Shen, R., Socci, N.D., Viale, A., Ferguson, M.L., Chen, Q.-R., Demchok, J.A., 
Dillon, L.A.L., Shaw, K.R.M., Sheth, M., Tarnuzzer, R., Wang, Z., Yang, L., 
Davidsen, T., Guyer, M.S., Ozenberger, B.A., Sofia, H.J., Bergsten, J., Eckman, 
J., Harr, J., Myers, J., Smith, C., Tucker, K., Winemiller, C., Zach, L.A., Ljubimova, 
J.Y., Eley, G., Ayala, B., Jensen, M.A., Kahn, A., Pihl, T.D., Pot, D.A., Wan, Y., 
Eschbacher, J., Foltz, G., Hansen, N., Hothi, P., Lin, B., Shah, N., Yoon, J.-G., 
34 
Lau, C., Berens, M., Ardlie, K., Beroukhim, R., Carter, S.L., Cherniack, A.D., 
Noble, M., Cho, J., Cibulskis, K., DiCara, D., Frazer, S., Gabriel, S.B., Gehlenborg, 
N., Gentry, J., Heiman, D., Kim, J., Jing, R., Lander, E.S., Lawrence, M., Lin, P., 
Mallard, W., Onofrio, R.C., Saksena, G., Schumacher, S., Sougnez, C., Stojanov, 
P., Tabak, B., Voet, D., Zhang, H., Zou, L., Dees, N.N., Ding, L., Fulton, L.L., 
Fulton, R.S., Kanchi, K.-L., Mardis, E.R., Wilson, R.K., Baylin, S.B., Andrews, 
D.W., Harshyne, L., Cohen, M.L., Devine, K., Sloan, A.E., VandenBerg, S.R., 
Berger, M.S., Carlin, D., Craft, B., Ellrott, K., Goldman, M., Goldstein, T., Grifford, 
M., Haussler, D., Ma, S., Ng, S., Salama, S.R., Sanborn, J.Z., Stuart, J., Swatloski, 
T., Waltman, P., Zhu, J., Foss, R., Frentzen, B., Friedman, W., McTiernan, R., 
Yachnis, A., Zheng, S., Vegesna, R., Mao, Y., Akbani, R., Bogler, O., Fuller, G.N., 
Liu, W., Liu, Y., Lu, Y., Mills, G., Protopopov, A., Ren, X., Sun, Y., Wu, C.-J., 
Yung, W.K.A., Zhang, J., Chen, K., Weinstein, J.N., Noushmehr, H., 
Weisenberger, D.J., Bootwalla, M.S., Lai, P.H., Triche, T.J., Jr, Van Den Berg, 
D.J., Laird, P.W., Gutmann, D.H., Lehman, N.L., VanMeir, E.G., Brat, D., Olson, 
J.J., Mastrogianakis, G.M., Devi, N.S., Zhang, Z., Bigner, D., Lipp, E., McLendon, 
R., 2013. The Somatic Genomic Landscape of Glioblastoma. Cell 155, 462–477. 
doi:10.1016/j.cell.2013.09.034 
Bressan, R.B., Dewari, P.S., Kalantzaki, M., Gangoso, E., Matjusaitis, M., Garcia-
Diaz, C., Blin, C., Grant, V., Bulstrode, H., Gogolok, S., Skarnes, W.C., Pollard, 
S.M., 2017. Efficient CRISPR/Cas9-assisted gene targeting enables rapid and 
precise genetic manipulation of mammalian neural stem cells. Development 
dev.140855–67. doi:10.1242/dev.140855 
Bruggeman, S.W.M., Hulsman, D., Tanger, E., Buckle, T., Blom, M., Zevenhoven, J., 
van Tellingen, O., van Lohuizen, M., 2007. Bmi1 controls tumor development in an 
Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell 12, 328–
341. doi:10.1016/j.ccr.2007.08.032 
Buenrostro, J.D., Giresi, P.G., Zaba, L.C., Chang, H.Y., Greenleaf, W.J., 2013. 
Transposition of native chromatin for fast and sensitive epigenomic profiling of 
open chromatin, DNA-binding proteins and nucleosome position. Nat Methods 10, 
1213–1218. doi:10.1038/nmeth.2688 
Buganim, Y., Faddah, D.A., Cheng, A.W., Itskovich, E., Markoulaki, S., Ganz, K., 
Klemm, S.L., van Oudenaarden, A., Jaenisch, R., 2012. Single-Cell Expression 
Analyses during Cellular Reprogramming Reveal an Early Stochastic and a Late 
Hierarchic Phase. Cell 150, 1209–1222. doi:10.1016/j.cell.2012.08.023 
Carén, H., Stricker, S.H., Bulstrode, H., Gagrica, S., Johnstone, E., Bartlett, T.E., 
Feber, A., Wilson, G., Teschendorff, A.E., Bertone, P., Beck, S., Pollard, S.M., 
2015. Glioblastoma Stem Cells Respond to Differentiation Cues but Fail to 
Undergo Commitment and Terminal Cell-Cycle Arrest. Stem Cell Reports 1–14. 
doi:10.1016/j.stemcr.2015.09.014 
Engelen, E., Akinci, U., Bryne, J.C., Hou, J., Gontan, C., Moen, M., Szumska, D., 
Kockx, C., van Ijcken, W., Dekkers, D.H.W., Demmers, J., Rijkers, E.-J., 
Bhattacharya, S., Philipsen, S., Pevny, L.H., Grosveld, F.G., Rottier, R.J., 
Lenhard, B., Poot, R.A., 2011. Sox2 cooperates with Chd7 to regulate genes that 
are mutated in human syndromes. Nat Genet 43, 607–611. doi:10.1038/ng.825 
Engström, P.G., Tommei, D., Stricker, S.H., Ender, C., Pollard, S.M., Bertone, P., 
2012. Digital transcriptome profiling of normal and glioblastoma-derived neural 
stem cells identifies genes associated with patient survival. Genome Med 4, 76. 
doi:10.1186/gm377 
Gangemi, R.M.R., Griffero, F., Marubbi, D., Perera, M., Capra, M.C., Malatesta, P., 
Ravetti, G.L., Zona, G.L., Daga, A., Corte, G., 2009. SOX2 silencing in 
glioblastoma tumor-initiating cells causes stop of proliferation and loss of 
35 
tumorigenicity. Stem Cells 27, 40–48. doi:10.1634/stemcells.2008-0493 
Gómez-López, S., Wiskow, O., Favaro, R., Nicolis, S.K., Price, D.J., Pollard, S.M., 
Smith, A., 2011. Sox2 and Pax6 maintain the proliferative and developmental 
potential of gliogenic neural stem cells In vitro. Glia 59, 1588–1599. 
doi:10.1002/glia.21201 
Kishi, M., Mizuseki, K., Sasai, N., Yamazaki, H., Shiota, K., Nakanishi, S., Sasai, Y., 
2000. Requirement of Sox2-mediated signaling for differentiation of early Xenopus 
neuroectoderm. Development 127, 791–800. 
Liu, F., Hon, G.C., Villa, G.R., Turner, K.M., Ikegami, S., Yang, H., Ye, Z., Bin Li, 
Kuan, S., Lee, A.Y., Zanca, C., Wei, B., Lucey, G., Jenkins, D., Zhang, W., Barr, 
C.L., Furnari, F.B., Cloughesy, T.F., Yong, W.H., Gahman, T.C., Shiau, A.K., 
Cavenee, W.K., Ren, B., Mischel, P.S., 2015. EGFR Mutation Promotes 
Glioblastoma through Epigenome and Transcription Factor Network Remodeling. 
Molecular Cell 60, 307–318. doi:10.1016/j.molcel.2015.09.002 
Lodato, M.A., Ng, C.W., Wamstad, J.A., Cheng, A.W., Thai, K.K., Fraenkel, E., 
Jaenisch, R., Boyer, L.A., 2013. SOX2 co-occupies distal enhancer elements with 
distinct POU factors in ESCs and NPCs to specify cell state. PLoS Genet. 9, 
e1003288. doi:10.1371/journal.pgen.1003288 
Lujan, E., Chanda, S., Ahlenius, H., Südhof, T.C., Wernig, M., 2012. Direct conversion 
of mouse fibroblasts to self-renewing, tripotent neural precursor cells. Proc. Natl. 
Acad. Sci. U.S.A. 109, 2527–2532. doi:10.1073/pnas.1121003109/-
/DCSupplemental 
Martynoga, B., Morrison, H., Price, D.J., Mason, J.O., 2005. Foxg1 is required for 
specification of ventral telencephalon and region-specific regulation of dorsal 
telencephalic precursor proliferation and apoptosis. Dev. Biol. 283, 113–127. 
doi:10.1016/j.ydbio.2005.04.005 
Mateo, J.L., van den Berg, D.L.C., Haeussler, M., Drechsel, D., Gaber, Z.B., Castro, 
D.S., Robson, P., Crawford, G.E., Flicek, P., Ettwiller, L., Wittbrodt, J., Guillemot, 
F., Ben Martynoga, 2015. Characterization of the neural stem cell gene regulatory 
network identifies OLIG2 as a multifunctional regulator of self-renewal. Genome 
Research 25, 41–56. doi:10.1101/gr.173435.114 
Mencarelli, M.A., Spanhol-Rosseto, A., Artuso, R., Rondinella, D., De Filippis, R., 
Bahi-Buisson, N., Nectoux, J., Rubinsztajn, R., Bienvenu, T., Moncla, A., Chabrol, 
B., Villard, L., Krumina, Z., Armstrong, J., Roche, A., Pineda, M., Gak, E., Mari, F., 
Ariani, F., Renieri, A., 2010. Novel FOXG1 mutations associated with the 
congenital variant of Rett syndrome. Journal of Medical Genetics 47, 49–53. 
doi:10.1136/jmg.2009.067884 
Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, Zhang X, 
Bernstein BE, Nusbaum C, Jaffe DB, et al.: Genome-scale DNA methylation maps 
of pluripotent and differentiated cells. Nature 2008, 454:766–770. 
Mikkelsen, T.S., Hanna, J., Zhang, X., Ku, M., Wernig, M., Schorderet, P., Bernstein, 
B.E., Jaenisch, R., Lander, E.S., Meissner, A., 2008. Dissecting direct 
reprogramming through integrative genomic analysis. Nature 454, 49–55. 
doi:10.1038/nature07056 
Miyoshi, G., Fishell, G., 2012. Dynamic FoxG1 Expression Coordinates the Integration 
of Multipolar Pyramidal Neuron Precursors into the Cortical Plate. Neuron 74, 
1045–1058. doi:10.1016/j.neuron.2012.04.025 
Pancrazi, L., Di Benedetto, G., Colombaioni, L., Sala, Della, G., Testa, G., Olimpico, 
F., Reyes, A., Zeviani, M., Pozzan, T., Costa, M., 2015. Foxg1 localizes to 
mitochondria and coordinates cell differentiation and bioenergetics. Proc. Natl. 
Acad. Sci. U.S.A. 112, 13910–13915. doi:10.1073/pnas.1515190112 
36 
Patel, A.P., Tirosh, I., Trombetta, J.J., Shalek, A.K., Gillespie, S.M., Wakimoto, H., 
Cahill, D.P., Nahed, B.V., Curry, W.T., Martuza, R.L., Louis, D.N., Rozenblatt-
Rosen, O., Suvà, M.L., Regev, A., Bernstein, B.E., 2014. Single-cell RNA-seq 
highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396–
1401. doi:10.1126/science.1254257 
Rheinbay, E., Suvà, M.L., Gillespie, S.M., Wakimoto, H., Patel, A.P., Shahid, M., 
Oksuz, O., Rabkin, S.D., Martuza, R.L., Rivera, M.N., Louis, D.N., Kasif, S., Chi, 
A.S., Bernstein, B.E., 2013. An Aberrant Transcription FactorNetwork Essential for 
Wnt Signalingand Stem Cell Maintenance in Glioblastoma. CellReports 3, 1567–
1579. doi:10.1016/j.celrep.2013.04.021 
Sato, A., Sunayama, J., Okada, M., Watanabe, E., Seino, S., Shibuya, K., Suzuki, K., 
Narita, Y., Shibui, S., Kayama, T., Kitanaka, C., 2012. Glioma-Initiating Cell 
Elimination by Metformin Activation of FOXO3 via AMPK. Stem Cells Transl Med 
1, 811–824. doi:10.5966/sctm.2012-0058 
Schildge, S., Bohrer, C., Beck, K., Schachtrup, C., 2013. Isolation and Culture of 
Mouse Cortical Astrocytes. JoVE. doi:10.3791/50079 
Seoane, J., Le, H.-V., Shen, L., Anderson, S.A., Massagué, J., 2004. Integration of 
Smad and forkhead pathways in the control of neuroepithelial and glioblastoma 
cell proliferation. Cell 117, 211–223. 
Singh, S.K., Clarke, I.D., Terasaki, M., Bonn, V.E., Hawkins, C., Squire, J., Dirks, P.B., 
2003. Identification of a cancer stem cell in human brain tumors 63, 5821–5828. 
Suvà, M.L., Rheinbay, E., Gillespie, S.M., Patel, A.P., Wakimoto, H., Rabkin, S.D., 
Riggi, N., Chi, A.S., Cahill, D.P., Nahed, B.V., Curry, W.T., Martuza, R.L., Rivera, 
M.N., Rossetti, N., Kasif, S., Beik, S., Kadri, S., Tirosh, I., Wortman, I., Shalek, 
A.K., Rozenblatt-Rosen, O., Regev, A., Louis, D.N., Bernstein, B.E., 2014. 
Reconstructing and Reprogramming the Tumor-Propagating Potentialof 
Glioblastoma Stem-like Cells. Cell 1–15. doi:10.1016/j.cell.2014.02.030 
Suvà, M.L., Riggi, N., Bernstein, B.E., 2013. Epigenetic reprogramming in cancer. 
Science 339, 1567–1570. doi:10.1126/science.1230184 
Verginelli, F., Perin, A., Dali, R., Fung, K.H., Lo, R., Longatti, P., Guiot, M.-C., Del 
Maestro, R.F., Rossi, S., di Porzio, U., Stechishin, O., Weiss, S., Stifani, S., 2013. 
Transcription factors FOXG1 and Groucho/TLE promote glioblastoma growth. 
Nature Communications 4, 2956. doi:10.1038/ncomms3956 
Vezzali, R., Weise, S.C., Hellbach, N., Machado, V., Heidrich, S., Vogel, T., 2016. The 
FOXG1/FOXO/SMAD network balances proliferation and differentiation of cortical 
progenitors and activates Kcnh3 expression in mature neurons. Oncotarget 7, 
37436–37455. doi:10.18632/oncotarget.9545 
Webb, A.E., Pollina, E.A., Vierbuchen, T., Urbán, N., Ucar, D., Leeman, D.S., Ben 
Martynoga, Sewak, M., Rando, T.A., Guillemot, F., Wernig, M., Brunet, A., 2013. 
FOXO3 Shares Common Targets with ASCL1 Genome-wide and Inhibits ASCL1-
Dependent Neurogenesis. CellReports 4, 477–491. 
doi:10.1016/j.celrep.2013.06.035 
Xuan, S., Baptista, C.A., Balas, G., Tao, W., Soares, V.C., Lai, E., 1995. Winged helix 
transcription factor BF-1 is essential for the development of the cerebral 
hemispheres. Neuron 14, 1141–1152. doi:10.1016/0896-6273(95)90262-7 
Zhang, Y., Sloan, S.A., Clarke, L.E., Caneda, C., Plaza, C.A., Blumenthal, P.D., 
Vogel, H., Steinberg, G.K., Edwards, M.S.B., Li, G., Duncan, J.A., III, Cheshier, 
S.H., Shuer, L.M., Chang, E.F., Grant, G.A., Gephart, M.G.H., Ben A Barres, 
2016. Purification and Characterization of Progenitor and Mature Human 
Astrocytes Reveals Transcriptional and Functional Differences with Mouse. 
Neuron 89, 37–53. doi:10.1016/j.neuron.2015.11.013 
Zhao, S., Nichols, J., Smith, A.G., Li, M., 2004. SoxB transcription factors specify 
37 
neuroectodermal lineage choice in ES cells. Mol Cell Neurosci 27, 332–342. 
doi:10.1016/j.mcn.2004.08.002 
 
  
38 
Figure legends 
Fig. 1 | FOXG1 and SOX2 are consistently expressed at high levels across GNS 
cells. A) Western blot to determine levels of FOXG1, SOX2 and OLIG2 expression 
across a set of GNS cells and normal NS controls. (B) ATAC-seq libraries were 
generated in NS and GNS cells. The 100 most differentially accessible sites across 
biological replicates of nine GNS cell lines and four NS cell lines were identified and 
are shown in a heatmap. (C) The most differentially accessible loci are enriched for 
key NS-specific TF motifs, most significantly the forkhead box motif. 
 
Fig. 2 | FOXG1/SOX2 overexpression can inhibit BMP-induced astrocyte 
differentiation. (A) Mouse NS cell lines provide an experimentally tractable model to 
study astrocyte differentiation. BMP4 treatment for 24 hr is sufficient to trigger efficient 
differentiation: cell cycle exit, adoption of astrocyte morphological features (flattened, 
star-shaped), and upregulation of Gfap. (B) 24 hr after replacing EGF/FGF-2 with 
BMP4, morphological changes are accompanied by downregulation of Ki67 and 
upregulation of Gfap (C) qRT-PCR analysis shows that, at a population level, BMP4 
treatment of NS cells at low density (10 cells/mm2) results in significant 
downregulation of Nestin and Olig2, and upregulation of astrocyte markers Gfap, 
Aqp4 and S100 beta. Mean +/- SD, n=3. Significance was assessed by Student’s t-
test with Holm-Sidak correction for multiple comparisons (* P ≤ 0.05, ** P ≤ 0.01, *** P 
≤ 0.001). (D) Western blot to show Foxg1 levels in clones picked following Cre 
treatment of Foxg1fl/fl NS cells demonstrate biallelic excision and absent protein 
expression. (E) Ki67 ICC was used to score proliferation in Foxg1 ablated cells. (F) A 
Doxycycline-inducible transgene cassette was designed to enable inducible co-
expression of FOXG1 and SOX2 (TRE, TET-responsive element; V5, V5 epitope tag; 
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P2A, porcine teschovirus-1 2A self-cleaving peptide sequence; PB, piggyBac; BSD, 
blasticidin resistance; IRES, internal ribosome entry site). Western blot (below) 
confirms dose-dependent increases in FOXG1 and SOX2 protein levels. (G) ICC for 
V5 and SOX2 confirms Dox-induced (1000 ng/ml) increase in V5-FOXG1 and SOX2 
levels.  (H) Clonal lines (F6, F11 and FS3) harboring the inducible cassettes (shown in 
Fig. 2F, S2E and S2F) were generated and transgene mRNA levels were determined 
by qRT-PCR following exposure to growth media supplemented with different 
concentrations of Dox. (I) Growth curves for mouse NS cells cultured in media 
supplemented with the mitogens EGF/FGF-2 (8 ng/ml each) plus BMP4 (2 ng/ml), 
either with or without induction of FOXG1/SOX2 overexpression by Dox (significance 
assessed by Student's t-test: FS3 +Dox vs FS3 -Dox (n=3), p<0.001 at all timepoints 
after 178 hours). (J) Phase contrast images of FS3 cells cultured in media 
supplemented with the mitogens EGF/FGF-2 (8 ng/ml each) plus BMP4 (2 ng/ml), with 
or without Dox supplementation, after 24 hr and 10 days.  
 
Fig. 3 | FOXG1/SOX2 drives reacquisition of NS cell identity in post-mitotic 
astrocytes. (A) Schematic of the experimental strategy used to test de-differentiation. 
Cells at clonal density (10 cells/mm2) are treated with BMP4 (10 ng/ml) for 24 hr and 
then switched to EGF/FGF-2 media, with or without transgene induction by Dox 
treatment. (B) EdU staining shows that no rapidly-cycling cells remain after 24 hr 
BMP4 treatment. 24 hr after plating in EGF/FGF-2 or BMP4, a 24 hr pulse of EdU was 
administered in media containing EGF/FGF-2. Representative images of EdU staining 
and quantification of % EdU positive cells are shown for each condition (Mean +/- SD, 
n=2 independent experiments. Scale bar: 100 μm) (C) Transgene dose determines 
the extent of colony formation after 10 days in EGF/FGF-2 (n=3 independent 
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experiments). Tumor competent IENS cells (Ink4a-Arf null; EGFRvIII overexpression) 
retain colony-forming ability after BMP treatment and serve as a positive control, whilst 
ANS4 cells serve as a negative control; below, example 10 cm dishes, for FS3 (no 
Dox), FS3 (Plus Dox, 1000 ng/ml) and IENS, after 24 hr BMP4 treatment and return to 
EGF/FGF-2 for 10 days. FS3 cells form colonies efficiently on transgene induction. (D) 
ICC for FS3 cells showing Gfap and Nestin protein levels after: 24 hr in EGF/FGF-2, 
24 hr in BMP4, return to EGF/FGF-2 for 10 days without Dox and return to EGF/FGF-
2 for 10 days with Dox. (E) Heatmap of the most differentially expressed transcripts 
across RNA-seq libraries at various time-points during de-differentiation; biological 
replicates are shown for each condition, with variability at early stages due to the low 
absolute numbers of cells that de-differentiate. (F) FS3 cells retain astrocytic and 
neuronal differentiation potential after long term expansion (~30 days), as shown by 
ICC for Gfap and Tuj1. (F) Mouse primary astrocytes were derived from P3 mouse 
cortex and the FOXG1/SOX2 inducible transgene introduced by lipofection. Following 
the described colony forming assay, colonies were scored two weeks following 
restoration of EGF/FGF-2. (G) A working model: in the presence of mitogens, FOXG1 
acts to prevent and reverse differentiation commitment; SOX2 is required for 
proliferation. 
 
Fig. 4 | ChIP-seq of FOXG1 targets in mouse NS cells. (A) FOXG1-V5 ChIP-Seq 
identifies 6897 binding peaks conserved across two separately derived mouse NS cell 
lines (Foxg1 ChIP mm10.bed). Motif analysis within the ChIP-seq peak regions for 
FOXG1-V5 reveals enrichment for the forkhead box motif, as well as helix-loop-helix, 
NF1-CTF and HMG-box motifs. (B) There is extensive overlap between FOXG1 and 
Sox2 bound regions with 3856 of 6897 FOXG1 bound regions also exhibiting Sox2 
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binding. (C) Shared bound regions were assigned to gene loci using the Stanford 
GREAT tool (FOXG1_Sox2 intersect gene associations.txt) and were found to be 
enriched for the gene ontology terms shown (FOXG1_Sox2 Intersect Gene 
Ontology.tsv) (D) RNA-seq demonstrates that Foxo3 is upregulated after BMP4 
treatment, along with astrocyte markers Gfap and Aqp4; by contrast, Nestin and 
epigenetic remodelling machinery Tet3 and Dnmt1 are downregulated. NS cell 
expression patterns return by day 14 (+Dox). 
 
Fig. 5 | FOXG1/SOX2 forced expression drives reduced expression of Foxo3 and 
genetic ablation of Foxo3 removes a barrier to cell cycle re-entry.  
(A) RNA-seq data for Foxo3 following return to EGF/FGF-2 for 1 or 4 days, with or 
without Dox. FPKM = Fragments Per Kilobase of transcript per Million mapped reads. 
(B) ICC for FoxO3 protein in FS3 cells plated at clonal density, after: 24 hr in 
EGF/FGF-2, 24 hr in BMP4 and return to EGF/FGF-2 for 4 days with or without Dox 
(4d = 4 days). (C) The Foxo3 locus is bound by FOXG1 and Sox2 at both the 
promoter region and a conserved intronic element (CIE) (indicated by red box). These 
regions enrich for H3K27 acetylation (top), a marker of active promoters and 
enhancers, and demonstrates high conservation across mammalian species (PhyloP). 
Clusters of the AAACA sequence comprising part of both Forkhead and Sox binding 
motifs are indicated by red arrows. Guide RNAs flanking the CIE were selected with a 
view to excision of this region by CRISPR/Cas9 (blue rectangles), along with 
sequencing primers for genotyping the resulting clones (yellow rectangles). (D) PCR 
genotyping to confirm biallelic deletion with expected single band in one line (termed 
FID11); FID11 retains the ability to respond to Dox and hence induce FOXG1-V5 
expression, as determined by ICC (below). (E) Deletion of the FOXG1/SOX2-bound 
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CIE results in derepression of Foxo3 mRNA expression in NS cell proliferation 
conditions (n=3, * P < 0.02), (F) Colony formation following Dox-induced 
FOXG1/SOX2 expression is abolished in CIE-deleted cells (Mean +/- SEM). (G) 
Western blot confirming the absence of FoxO3 protein expression in FOD3 - a clonal 
cell line harboring a frameshift indel mutation on the non-targeted allele. (H) Following 
BMP treatment, Foxo3-/- FOD3 cells divide slowly in growth conditions (doubling time 
~6 days), in contrast to Foxo3+/+ controls which remain cycle arrested. FOXG1/SOX2 
induction, or treatment of FOD3 cells with 5-azacytidine drives rapid colony formation 
and proliferation to confluence (doubling time ~24 hours). (I) Colony forming assay at 
10 days for de-differentiation responses in Foxo3-/- cells and those treated with 5-
Azacytidine, with and without Dox. (J) ICC for Nestin and Gfap. The proportion of cells 
positive for nestin in representative colonies is indicated beneath the panels. See also 
Fig. S5D. 
 
 
Fig. 6 | FOXG1 overexpression results in increased activation of regulators of 
DNA methylation and these may affect key polycomb target genes 
(A) Colony numbers upon return to self-renewal media with or without Dox (1000 
ng/ml) for 10 days, following 24 hr BMP4 treatment. Induction of FOXG1 alone in two 
independent lines (F6 and F11) induced colony formation at higher efficiency than in 
FS3. Induction of SOX2 alone (TS15) was not sufficient to drive colony formation. (B) 
Example colony forming assay for F6 showing colonies after 10 days in EGF/FGF-2, 
only on the addition of Dox. (C) RNA-seq confirms that following FOXG1 induction by 
Dox, BMP4-treated F6 cells re-acquire an NS cell-like transcriptional signature. 
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Alignment with ChIP-seq data for FOXG1 and SOX2 (left) indicates that many of the 
genes activated on de-differentiation are bound by FOXG1 and SOX2. (D) qRT-PCR 
analysis of Dnmt1, Dnmt3b and Tet3 (Mean +/- SD, n=4. Significance assessed by 
two-way ANOVA with Bonferroni post-hoc test. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, 
**** P ≤ 0.0001). (E) Analysis of enrichment of RRBS identified DMRs near genes 
marked by polycomb in mouse ES cells (ES), neural stem cells (NS) and brain. Shown 
are the % CpGs assayed by RRBS found near polycomb marked genes (Background, 
grey) compared to those in significant DMRs after either 24 hr or 10 days of 
differentiation (BMP increased methylation, blue and BMP decreased, orange). 
Significance was assessed with Fisher’s exact tests (** P < 0.01, *** P < 0.001; n = 3). 
(F) Mean methylation profiles observed by RRBS in the Foxo3 promoter including the 
locations of its CpG island (CGI) and Foxg1 ChIP-seq peak. Significant DMRs are 
shown in red together with an additional DMR that did not reach statistical significance 
in all replicates of the experiment (pale red).  
 
Fig. 7 | Genetic ablation of FOXG1 in human GBM stem cells using Cas9-
assisted gene targeting. (A) CRISPR/Cas-based gene targeting was used to 
knockout FOXG1 in G7 cells, and no protein was detectable by western blot, with a 
frameshift mutation demonstrated on the second FOXG1 allele in this clone (see Fig. 
S7). (B) Growth curve displaying percentage confluence over time for G7 and G7 
FOXG1-/- cell lines, indicating that the FOXG1-/- clone proliferates at a similar rate to 
parental controls in vitro. (C) Upon xenotransplantation, wild type G7 cells expressing 
a GFP reporter form invasive tumours, but FOXG1-/- derivatives fail to do so (n=4 for 
each cell line). (D) IHC analysis of xenografts reveals the G7 FOXG1 mutant cells 
display: increased expression of astrocyte markers S100 beta (red) and GFAP (grey), 
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reduced expression of NESTIN (grey) (E), increased expression of FOXO3 (F) and 
decreased expression of Ki67 (red) (G). (H) Quantitation of the percentage of cells 
positive for GFAP, Ki67 and FOXO3, from IHC.  (I) Working model of FOXG1 and 
SOX2 function in GBM based on this study (green cell, post-mitotic or quiescent 
astrocytes; brown/grey cell, radial glia-like proliferative neural stem cell). Scale bar: 10 
μm; scale bar for higher magnification images in panel F: 20 μm. Students t test: n =4,  
P  <0.005). 
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